ADC Therapeutics SA - notizie pubblicate 183 - letture 4.614
ADC THERAPEUTICS SA
RBC Capital Markets Global Healthcare Conference Presentation
Corporate presentation 2q 2024 forward-looking statements this presentation and any accompanying oral presentation have been prepared by adc therapeutics sa ("adc therapeutics ...
ADC THERAPEUTICS SA
Regulation FD Presentation - Form 8-K
The text version of this document is not available. you can access the original document here. attachments original link original document permalink disclaimer adc therapeutics sa ...
ADC THERAPEUTICS SA
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
ADC THERAPEUTICS SA
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
ADC THERAPEUTICS SA
ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare Conference
View all news adc therapeutics to participate in 2024 rbc capital markets global healthcare conference may 09, 2024 lausanne, switzerland, may 09, 2024 (globe newswire) -- adc ther ...
ADC THERAPEUTICS SA
Material Event - Form 8-K
Item 8.01. other events. on may 6, 2024, adc therapeutics sa (the "company") entered into an underwriting agreement (the "underwriting agreement") with jefferie ...
ADC THERAPEUTICS SA
Supplemental Prospectus - Form 424B5
Filed pursuant to rule 424(b)(5) registration no. 333-270570 prospectus supplement (to prospectus dated march 14, 2024) adc therapeutics sa 13,411,912 common shares pre-funded warr ...
ADC THERAPEUTICS SA
1Q 2024 Earnings Call
1q 2024 earnings call may 6, 2024 agenda 01 02 q&a ameet mallik business update chief executive officer pepe carmona financial update chief financial officer kristen harrington ...
ADC THERAPEUTICS SA
ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded Warrants
View all news adc therapeutics announces $105 million underwritten offering of common shares and pre-funded warrants may 06, 2024 lausanne, switzerland, may 06, 2024 (globe newswir ...
ADC THERAPEUTICS SA
Supplemental Prospectus - Form 424B5
Filed pursuant to rule 424(b)(5) registration no. 333-270570 the information in this preliminary prospectus supplement is not complete and may be changed. this preliminary prospect ...
ADC THERAPEUTICS SA
Quarterly Report for Quarter Ending March 31, 2024 (Form 10-Q)
Adc-20240331 table of contents united states securities and exchange commission washington, d.c. 20549 form 10-q (mark one) ☒ quarterly report pursuant to section 13 or 15(d) of ...
ADC THERAPEUTICS SA
ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
View all news adc therapeutics reports first quarter 2024 financial results and provides business updates may 06, 2024 zynlonta® (loncastuximab tesirine-lpyl) net sales of $17.8 m ...
ADC THERAPEUTICS SA
ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA® in Patients with Relapsed/Refractory Marginal Zone Lymphoma
View all news adc therapeutics announces initial data from investigator-initiated phase 2 clinical trial of zynlonta® in patients with relapsed/refractory marginal zone lymphoma m ...
ADC THERAPEUTICS SA
ADC Therapeutics to Host First Quarter 2024 Financial Results and Pipeline Update Conference Call on May 6, 2024
View all news adc therapeutics to host first quarter 2024 financial results and pipeline update conference call on may 6, 2024 may 01, 2024 lausanne, switzerland, may 01, 2024 (glo ...
ADC THERAPEUTICS SA
Additional Proxy Soliciting Materials - Form DEFA14A
United states securities and exchange commission washington, d.c. 20549 schedule 14a proxy statement pursuant to section 14(a) of the securities exchange act of 1934 filed by the r ...
Sei un professionista?
Abbiamo ricevuto 2.400 richieste di consulenza, pubblica il tuo profilo premium
per ricevere contatti e acquisire nuovi clienti